Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Dyslipidemia

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 15 articles:
HTML format



Single Articles


    September 2022
  1. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    PubMed     Abstract available


    July 2021
  2. BJORNSTAD P, Drews KL, Caprio S, Gubitosi-Klug R, et al
    Long-Term Complications in Youth-Onset Type 2 Diabetes.
    N Engl J Med. 2021;385:416-426.
    PubMed     Abstract available


    March 2021
  3. GIBBONS GH, Seidman CE, Topol EJ
    Conquering Atherosclerotic Cardiovascular Disease - 50 Years of Progress.
    N Engl J Med. 2021;384:785-788.
    PubMed    


    February 2021
  4. RAAL FJ, Gaudet D, Gusarova V
    Evinacumab for Homozygous Familial Hypercholesterolemia. Reply.
    N Engl J Med. 2021;384:e17.
    PubMed    


  5. XU HG
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    


  6. LUO F, Das A, Fang Z
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    


  7. AGIRBASLI M
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    


    January 2021
  8. GAUDET D, Ruzza A, Santos RD
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. Reply.
    N Engl J Med. 2021;384:84-85.
    PubMed    


  9. SINGH A, Mittal S, Kazimuddin M
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:84.
    PubMed    


    December 2020
  10. MARTIN SS
    Factoring in ANGPTL3 When LDL Is Refractory.
    N Engl J Med. 2020;383:2385-2386.
    PubMed    


    November 2020
  11. SHAW AT, Bauer TM, de Marinis F, Felip E, et al
    First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    N Engl J Med. 2020;383:2018-2029.
    PubMed     Abstract available


  12. ROSENSON RS, Burgess LJ, Ebenbichler CF, Baum SJ, et al
    Evinacumab in Patients with Refractory Hypercholesterolemia.
    N Engl J Med. 2020 Nov 15. doi: 10.1056/NEJMoa2031049.
    PubMed     Abstract available


    October 2020
  13. DE FERRANTI SD
    Evolocumab in Children with Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020;383:1385-1386.
    PubMed    


    August 2020
  14. SANTOS RD, Ruzza A, Hovingh GK, Wiegman A, et al
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2019910.
    PubMed     Abstract available


    March 2020
  15. RAAL FJ, Kallend D, Ray KK, Turner T, et al
    Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa1913805.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: